MDM2 and neoplasm: There are also antagonists targeting the interaction of MDM2 and p53, such as Nutlin-3, which activate the p53 pathway in chemoresistant neuroblastoma with wild-type p53, inhibit primary tumor growth, and reduce tumor metastasis in mice carrying chemoresistant neuroblastoma xenografts (66).